Caredx Stock News

SOUTH SAN FRANCISCO, Calif., April 28, 2022 (GLOBE NEWSWIRE) -- CareDx, Inc. (Nasdaq: CDNA) – The Transplant Company™ focused on the discovery, development, and commercialization of clinically d

SOUTH SAN FRANCISCO, Calif., April 27, 2022 (GLOBE NEWSWIRE) -- CareDx, Inc. (Nasdaq: CDNA) – The Transplant Company™ focused on the discovery, development, and commercialization of clinically dif

CareDx CEO and President, Reg Seeto, Joins ISHLT Foundation Global Steering Committee Focused on Driving Innovations for Heart and Lung Transplant Patients CareDx CEO and President, Reg Seeto, Joins I

Upgrades RBC Capital upgraded the previous rating for United States Steel Corp (NYSE:X) from Sector Perform to Outperform. United States Steel earned $3.64 in the fourth quarter, compared to $0.27 in

CareDx Announces that OTTR Patient Management Software Now Validated for SMART on FHIR CareDx Announces that OTTR Patient Management Software Now Validated for SMART on FHIR

SOUTH SAN FRANCISCO, Calif., April 21, 2022 (GLOBE NEWSWIRE) -- CareDx, Inc. (Nasdaq: CDNA) – The Transplant Company™ focused on the discovery, development, and commercialization of clinically d

Data Highlights Clinical Utility of CareDx Solutions, Including Findings from Surveillance HeartCare Outcomes Registry (SHORE) Demonstrating Power of Multimodality Assessment for More Precise Interven

CareDx Testing Services Have Been Used in Over 30,000 Heart Transplant Patients and Over 90 Percent of Centers in the United States CareDx Testing Services Have Been Used in Over 30,000 Heart Transpla

Symposium, “Improved Precision with a Multimodality Approach,” Reviews Innovative Solutions for a More Holistic View of Allograft Health Symposium, “Improved Precision with a Multimodality Appro

SOUTH SAN FRANCISCO, Calif., March 30, 2022 (GLOBE NEWSWIRE) -- CareDx, Inc. (Nasdaq: CDNA) – The Transplant Company™ focused on the discovery, development, and commercialization of clinically d

New Features Aim to Help More Patients with Kidney Failure Receive an Organ Transplant New Features Aim to Help More Patients with Kidney Failure Receive an Organ Transplant

Jury Finds Natera Falsely Advertised its Prospera Kidney Transplant Technology Jury Finds Natera Falsely Advertised its Prospera Kidney Transplant Technology

EDEN PRAIRIE, Minn., March 16, 2022 (GLOBE NEWSWIRE) -- Miromatrix Medical Inc. (NASDAQ: MIRO ), a life sciences company pioneering a novel technology for bioengineering fully transplantable organs to help save and improve patients'' lives, announced its participation in CareDx''s Xenotransplantation Innovation Day, a virtual event that will feature a leading panel of transplant experts who will share the latest advancements in the field. CareDx''s Xenotransplantation Innovation Day will be held on March 22, 2022, from 11:00 am to 12:00 pm Central Time / 12:00 pm to 1:00 pm Eastern Time. The presentations and panel discussions will be held in a virtual format to enable a wide audience to learn from these experts. The symposium will include an update on the world''s first living pig-to-human heart transplant from the University of Maryland School of Medicine, an update on the world''s first transplant of a gene-edited pig kidney from NYU Langone Health, and a development update regarding human-compatible organs from eGenesis and an update on bioengineered livers and kidneys for transplant from Miromatrix.

LITHIA, Fla., March 16, 2022 (GLOBE NEWSWIRE) -- The nonprofit Transplant Recipients International Organization (TRIO) today praised a federal jury''s $44.9 million verdict award to CareDx, Inc., finding that a transplant test provider and its senior executives intentionally and recklessly made misleading statements about the veracity of its test for kidney transplant effectiveness. "The verdict handed down on Monday ultimately benefits patients whose lives depend on rigorous, reliable science and clinical excellence," said TRIO President James … Full story available on Benzinga.com

Genetic testing company Natera Inc owes rival CareDx Inc $44.9 million for making false claims about the effectiveness of Natera''s Prospera test for assessing the risk that a person''s body will reject a kidney transplant, a Delaware jury said.